FDA approves AstraZeneca's Lynparza combo for adults with BRCA-mutated prostate cancer
In April, an FDA adcomm gave the thumbs up to AstraZeneca’s blockbuster PARP inhibitor Lynparza label expansion into prostate cancer — but only for patients whose tumors have a BRCA mutation.
On Wednesday, the FDA followed the adcomm’s recommendation and approved Lynparza in combination with abiraterone (Zytiga) and prednisone or prednisolone for adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.